While institutions own 26% of Acrivon Therapeutics, Inc. (NASDAQ:ACRV), private equity firms are its largest shareholders with 50% ownership [Yahoo! Finance]
Acrivon Therapeutics, Inc. (ACRV)
Company Research
Source: Yahoo! Finance
The top 3 shareholders own 57% of the company Institutions own 26% of Acrivon Therapeutics To get a sense of who is truly in control of Acrivon Therapeutics, Inc. ( NASDAQ:ACRV ), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company, around 50% to be precise, is private equity firms. Put another way, the group faces the maximum upside potential (or downside risk). And institutions on the other hand have a 26% ownership in the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. Let's delve deeper into each type of owner of Acrivon Therapeutics, beginning with the chart below. View our latest analysis for Acrivon Therapeutics What Does The Institutional Ownership Tell Us About Acrivon Therapeutics? Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often b
Show less
Read more
Impact Snapshot
Event Time:
ACRV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRV alerts
High impacting Acrivon Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACRV
News
- Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $25.00 price target on the stock.MarketBeat
- Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target raised by analysts at HC Wainwright from $20.00 to $22.00. They now have a "buy" rating on the stock.MarketBeat
- Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights [Yahoo! Finance]Yahoo! Finance
- Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsGlobeNewswire
- Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season? [Yahoo! Finance]Yahoo! Finance
ACRV
Earnings
- 5/14/24 - Beat
ACRV
Sec Filings
- 5/16/24 - Form 4
- 5/16/24 - Form 4
- 5/16/24 - Form 4
- ACRV's page on the SEC website